Lewis G S, Wang S, Taylor J B
USDA, Agricultural Research Service, U.S. Sheep Experiment Station, Range Sheep Production Efficiency Research Unit, Dubois, Idaho 83423.
Transl Anim Sci. 2017 Dec 1;1(4):585-591. doi: 10.2527/tas2017.0065. eCollection 2017 Dec.
Factors affecting the decay of maternally derived IgG and ability of neonatal lambs to produce protective amounts of their own IgG are not well understood. Thus, we conducted 3 experiments to quantify the 1) response of pregnant ewes to ovalbumin immunization, 2) antiovalbumin antibody (OV-IgG) transfer to lambs, 3) changes over time in OV-IgG in lambs, and 4) response of young lambs to ovalbumin immunization. In Exp. 1, ewes ( = 10/group) either received control (adjuvant + saline) or ovalbumin (ovalbumin + adjuvant + saline) injections at ≈ 42 and 14 d prepartum. Ovalbumin increased ( < 0.001) ewe serum and colostrum OV-IgG. Serum OV-IgG was greater ( < 0.0001) in lambs from ovalbumin-treated than in lambs from control ewes. In Exp. 2, lambs ( = 20/group), which were from ewes that had received ovalbumin prepartum, were given either control or ovalbumin injections on d 1 and 15 of age. From d 1 to 15, maternally derived OV-IgG was less ( < 0.04) in ovalbumin-treated than in control lambs. After d 15, OV-IgG was greater ( < 0.001) in ovalbumin-treated than in control lambs. In Exp. 3, lambs ( = 20/group), which were from ewes naïve to ovalbumin, received 1 of 4 treatments: 1) d-1 + d-15 control injections; 2) d-1 + d-15 ovalbumin; 3) d-28 + d-42 control; and 4) d-28 + d-42 ovalbumin. In d-1 + d-15 ovalbumin lambs, OV-IgG increased ( < 0.001) from d 7 to 21 after treatment and then decreased ( < 0.004) after d 28. In d-28 + d-42 ovalbumin lambs, OV-IgG increased ( < 0.001) steadily until d 21 after treatment and then stabilized after d 21. At ≈ 159 d of age, lambs in each group received injections consistent with their original type. After the d-159 treatment, ovalbumin injection increased ( < 0.0001) OV-IgG, and the injection type × time interaction was significant ( < 0.0001). In d-28 + d-42 ovalbumin lambs, OV-IgG just before the d-159 injections was greater ( < 0.006) than that in the other groups. In this study, late pregnant ewes produced OV-IgG after ovalbumin injections and then transferred OV-IgG to lambs via colostrum. Ovalbumin treatment of young lambs reduced circulating maternally derived OV-IgG, but it also induced an immune response in the lambs. Overall, our results support recommendations to vaccinate ewes against common pathogens during late pregnancy and to ensure that lambs receive adequate colostrum soon after birth.
影响母源IgG衰减的因素以及新生羔羊产生自身足够量保护性IgG的能力尚未得到充分了解。因此,我们进行了3项实验,以量化1)怀孕母羊对卵清蛋白免疫的反应,2)抗卵清蛋白抗体(OV-IgG)向羔羊的转移,3)羔羊体内OV-IgG随时间的变化,以及4)幼龄羔羊对卵清蛋白免疫的反应。在实验1中,母羊(每组10只)在产前约42天和14天分别接受对照(佐剂+生理盐水)或卵清蛋白(卵清蛋白+佐剂+生理盐水)注射。卵清蛋白增加了(P<0.001)母羊血清和初乳中的OV-IgG。来自经卵清蛋白处理母羊的羔羊血清OV-IgG高于(P<0.0001)来自对照母羊的羔羊。在实验2中,来自产前接受卵清蛋白处理母羊的羔羊(每组20只)在1日龄和15日龄时分别接受对照或卵清蛋白注射。从1日龄到15日龄,经卵清蛋白处理的羔羊体内母源OV-IgG低于(P<0.04)对照羔羊。15日龄后,经卵清蛋白处理的羔羊体内OV-IgG高于(P<0.001)对照羔羊。在实验3中,来自未接触过卵清蛋白母羊的羔羊(每组20只)接受4种处理中的1种:1)-1日龄+-15日龄对照注射;2)-1日龄+-15日龄卵清蛋白;3)-28日龄+-42日龄对照;4)-28日龄+-42日龄卵清蛋白。在-1日龄+-15日龄注射卵清蛋白的羔羊中,处理后7至21天OV-IgG增加(P<0.001),然后在28天后下降(P<0.004)。在-28日龄+-42日龄注射卵清蛋白的羔羊中,OV-IgG在处理后21天前稳步增加(P<0.001),然后在21天后稳定。在约159日龄时,每组羔羊接受与其原始处理类型一致的注射。在-159日龄处理后,卵清蛋白注射增加了(P<0.0001)OV-IgG,且注射类型×时间交互作用显著(P<0.0001)。在-28日龄+-42日龄注射卵清蛋白的羔羊中,-159日龄注射前的OV-IgG高于(P<0.006)其他组。在本研究中,妊娠后期母羊在注射卵清蛋白后产生OV-IgG,然后通过初乳将OV-IgG转移给羔羊。对幼龄羔羊进行卵清蛋白处理可降低循环中的母源OV-IgG,但也会诱导羔羊产生免疫反应。总体而言,我们的结果支持在妊娠后期给母羊接种针对常见病原体的疫苗以及确保羔羊出生后尽快摄入足够初乳的建议。